Q-omics provides the consensus-scored CDRT15P8 profile across patient tissues and cancer cell-line models. CDRT15P8 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, CDRT15P8 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, CDRT15P8 RNA expression shows 4,841 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LIHC, BRCA, and STAD as cancer lineages where CDRT15P8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDRT15P8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDRT15P8 survival associations across molecular data types. CDRT15P8 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDRT15P8 RNA expression–survival associations across cancer types. High CDRT15P8 expression shows unfavorable associations in LIHC, STAD, UCS, READ and KICH, but favorable associations in MESO. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for CDRT15P8 RNA expression.
This table summarizes CDRT15P8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for CDRT15P8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDRT15P8 shows lower tumor expression in LUSC and THCA and higher tumor expression in BRCA and LIHC. The BRCA box plot shows higher CDRT15P8 RNA expression in tumor versus normal tissue (log2 FC = +0.032, t-test p = .009).
This table shows molecular features associated with CDRT15P8 in patient tissues and cancer cell lines. In patient samples, CDRT15P8 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
